FULGENT GENETIC (NASDAQ:FLGT) had its price objective trimmed by Credit Suisse Group from $10.00 to $7.50 in a report published on Tuesday. The firm currently has an outperform rating on the stock.

Other equities analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of FULGENT GENETIC from a sell rating to a hold rating in a research note on Monday, July 10th. Raymond James Financial, Inc. downgraded shares of FULGENT GENETIC from an outperform rating to a mkt perform rating in a research note on Tuesday. Piper Jaffray Companies restated an overweight rating and issued a $7.00 price target (down from $10.00) on shares of FULGENT GENETIC in a research note on Wednesday, August 9th. Finally, ValuEngine upgraded shares of FULGENT GENETIC from a sell rating to a hold rating in a research note on Monday, October 2nd. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $7.25.

FULGENT GENETIC (NASDAQ:FLGT) opened at $3.32 on Tuesday. FULGENT GENETIC has a one year low of $2.72 and a one year high of $13.90. The company has a market cap of $59.52 and a PE ratio of 167.75.

ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/fulgent-genetic-flgt-given-new-7-50-price-target-at-credit-suisse-group/1695885.html.

Institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN grew its stake in FULGENT GENETIC by 2,046.0% during the first quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock worth $118,000 after buying an additional 10,230 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in FULGENT GENETIC during the first quarter worth about $122,000. Finally, William Blair Investment Management LLC grew its stake in FULGENT GENETIC by 10.4% during the second quarter. William Blair Investment Management LLC now owns 640,219 shares of the company’s stock worth $4,091,000 after buying an additional 60,508 shares in the last quarter. Hedge funds and other institutional investors own 16.78% of the company’s stock.

FULGENT GENETIC Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for FULGENT GENETIC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FULGENT GENETIC and related companies with Analyst Ratings Network's FREE daily email newsletter.